Pradžia › Šlapimo pūslės vėžys › Texas › Dallas
Šlapimo pūslės vėžys klinikiniai tyrimai Dallas, TX
27 tyrimai dėl Šlapimo pūslės vėžys ieško dalyvių vietose Dallas ir aplinkui (apytiksliai 30 mylių spinduliu). Atidarykite tyrimą, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Renkami dalyviai2 fazė
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
Renkami dalyviai1/2 fazė
- UT Southwestern Medical Center, Dallas
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Renkami dalyviai2 fazė
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Renkami dalyviai1 fazė
- Cancer Center Outpatient Building, Dallas
- The University of Texas Southwestern Medical Center, Dallas
- UT Southwestern Medical Center - West Campus Building, Dallas
- ir dar 2
DESTINY-PANTUMOUR04
Renkami dalyviaiStebimasis tyrimas
- Research Site, Dallas
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Renkami dalyviai3 fazė
- Parkland Health and Hospital System, Dallas
- UT Southwestern Medical Center, Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Renkami dalyviaiStebimasis tyrimas
- UT Southwestern Medical Center, Dallas
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Renkami dalyviai2 fazė
- Urology Clinics of North Texas, PLLC, Dallas
- UT Southwestern Medical Center, Dallas
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
Renkami dalyviaiStebimasis tyrimas
- University of Texas Southwestern Medical Center, Dallas
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Renkami dalyviai1 fazė
- University of Texas Southwestern, Dallas
- Texas Oncology, P.A, Dallas
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Renkami dalyviai2/3 fazė
- Research Site, Dallas
Measuring Surgical Recovery After Radical Cystectomy
Renkami dalyviaiStebimasis tyrimas
- University of Texas - Southwestern, Dallas
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Renkami dalyviai3 fazė
- Parkland Memorial Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Renkami dalyviai1/2 fazė
- UT Southwestern Medical Center, Dallas
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Renkami dalyviai2 fazė
- Baylor Scott & White Research Institute, Dallas
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Renkami dalyviai3 fazė
- Research Site, Dallas
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Renkami dalyviai2 fazė
- Baylor Scott and White Research Institute, Dallas
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Renkami dalyviai1 fazė
- NEXT Dallas, Dallas
Predicting BCG Response
Renkami dalyviaiStebimasis tyrimas
- University of Texas Southwestern, Dallas
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Renkami dalyviai
- UT Southwestern Medical Center, Dallas
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
Renkami dalyviaiStebimasis tyrimas
- UT Southwestern Medical Center, Dallas
Bladder Cancer Screening Trial
Renkami dalyviai
- University of Texas Southwestern Medical Center, Dallas
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Renkami dalyviai1/2 fazė
- NEXT Oncology - Dallas, Dallas
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Renkami dalyviai1 fazė
- Mary Crowley Cancer Research, Dallas
- Baylor University Medical Center, Dallas
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Renkami dalyviaiStebimasis tyrimas
- UT Southwestern Medical Center at Dallas, Dallas
Blue Light Cystoscopy With Cysview® Registry
Renkami dalyviaiStebimasis tyrimas
- UT Southwestern, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Renkami dalyviaiStebimasis tyrimas
- Massive Bio SYNERGY-AI site, Dallas
Šlapimo pūslės vėžys tyrimai kituose miestuose
- New York City, NY35 tyrimai
- Nashville, TN31 tyrimas
- Houston, TX31 tyrimas
- Boston, MA26 tyrimai
- Washington, DC26 tyrimai
- Los Angeles, CA24 tyrimai
- Baltimore, MD24 tyrimai
- St. Louis, MO22 tyrimai
- Philadelphia, PA21 tyrimas
- Seattle, WA21 tyrimas
- Edison, NJ21 tyrimas
- Chicago, IL21 tyrimas
Kiti tyrimai Dallas
- Krūties vėžys55 tyrimai
- Nedidelinių ląstelių plaučių vėžys52 tyrimai
- Metastatinis vėžys42 tyrimai
- Širdies nepakankamumas42 tyrimai
- Vėžys (visų tipų)37 tyrimai
- Prostatos vėžys36 tyrimai
- Storosios ir tiesiosios žarnos vėžys33 tyrimai
- Nutukimas30 tyrimai
- Kiaušidžių vėžys28 tyrimai
- Plaučių vėžys27 tyrimai
- Endometrio vėžys24 tyrimai
- Širdies ir kraujagyslių ligos23 tyrimai
Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.